Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.